PLK1 and acute myeloid leukemia: Notably, the drug with better results in both the virtual screen and the drug sensitivity analysis is Volasertib, a Plk1 inhibitor, that has reached phase III clinical trials for adult acute myeloid leukaemia patients ineligible for intensive remission induction therapy (Döhner et al., 2016).